A pre-operative window study evaluating the biological effects of the RANK-Ligand (RANKL) inhibitor Denosumab on normal breast tissue from BRCA1 and BRCA2 mutation carriers and high risk, non-BRCA carriers.

Trial Profile

A pre-operative window study evaluating the biological effects of the RANK-Ligand (RANKL) inhibitor Denosumab on normal breast tissue from BRCA1 and BRCA2 mutation carriers and high risk, non-BRCA carriers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Denosumab (Primary)
  • Indications Breast cancer
  • Focus Pharmacogenomic; Proof of concept; Therapeutic Use
  • Acronyms BRCA-D
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jul 2015 Planned number of patients changed from 30 to 40, according to Australian New Zealand Clinical Trials Registry record.
    • 20 Nov 2014 Status changed from not yet recruiting to recruiting, according to Australian New Zealand Clinical Trials Registry record.
    • 05 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top